TY - JOUR
T1 - Reduction of hospitalization and transfusion support in patients with acute promyelocytic leukemia treated with arsenic trioxide plus all-trans retinoic acid compared to chemotherapy plus all-trans retinoic acid
AU - Sica, Simona
PY - 2019
Y1 - 2019
N2 - Acute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The
discovery of the molecular pathogenesis has led to the first targeted therapy for acute
leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based
chemotherapy obtaining high response rates, but some potential longterm sequelae are
described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to
standard chemotherapy in a pivotal trial with excellent results both in terms of complete
AB - Acute promyelocytic leukemia (APL) is a variant of AML characterized by t (15; 17). The
discovery of the molecular pathogenesis has led to the first targeted therapy for acute
leukemia: all-trans retinoic acid (ATRA). ATRA is usually associated to anthracycline-based
chemotherapy obtaining high response rates, but some potential longterm sequelae are
described [1]. The introduction of arsenic trioxide (ATO)[2] and ATRA was compared to
standard chemotherapy in a pivotal trial with excellent results both in terms of complete
KW - transfusion support promyelocytic leukemia
KW - transfusion support promyelocytic leukemia
UR - http://hdl.handle.net/10807/155702
U2 - 10.1080/10428194.2018.1522436
DO - 10.1080/10428194.2018.1522436
M3 - Article
SN - 1042-8194
SP - 1330
EP - 1338
JO - LEUKEMIA & LYMPHOMA
JF - LEUKEMIA & LYMPHOMA
ER -